Adoption And Reimbursement UncertaintyThe novel nature of multi-cancer early detection technology creates adoption and reimbursement uncertainty that could delay uptake and payor coverage.
Cash Burn And Runway RiskAnalysts warn that cash burn, while reduced, remains a risk that could pressure the company's financial runway if cost control or commercial traction weakens.
Pricing PressureSequential declines in effective selling prices point to pricing pressure that could compress revenue per test if lower pricing persists.